MediGene has filed a patent for methods and uses of antibodies that target the Cß1 or Cß2 chain of a T cell receptor (TCR). The invention describes an in vitro method for generating a T cell population enriched for T cells expressing a desired antigen-specific recombinant TCR. The method involves incubating T cells with an anti-Cß antibody, depleting bound T cells, introducing a recombinant TCR containing a Cß chain, and enriching T cells expressing the recombinant TCR using the anti-Cß antibody. GlobalData’s report on MediGene gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights MediGene AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MediGene, Adeno-associated virus vectors was a key innovation area identified from patents. MediGene's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Enrichment of t cells expressing recombinant t cell receptors

Source: United States Patent and Trademark Office (USPTO). Credit: MediGene AG

A recently filed patent (Publication Number: US20230287345A1) describes an in vitro method for generating a T cell population enriched for T cells expressing a recombinant T cell receptor (TCR). The method involves several steps. First, a composition comprising T cells is incubated with an anti-Cß antibody, specifically an anti-Cß1 or anti-Cß2 antibody. The T cells bound to the anti-Cß antibody are then depleted. Next, a recombinant TCR containing a Cß chain to which the anti-Cß antibody binds is introduced into the T cell population obtained in the previous step. Finally, the T cells expressing the recombinant TCR are enriched in the population using the anti-Cß antibody.

According to the patent, the method aims to achieve a high percentage of T cells expressing the recombinant TCR in the final population. The patent claims that at least 60% of the T cell population obtained in the enrichment step should express the recombinant TCR, with higher percentages preferred (at least 70%, 80%, or 90%).

The enrichment of T cells expressing the recombinant TCR can be achieved by incubating the cells with the anti-Cß antibody and isolating the T cells bound to the antibody. In some embodiments, the isolated T cells can be further expanded.

The patent also mentions the use of a retroviral particle for introducing the recombinant TCR into the T cell population. The composition of T cells used in the method can be obtained from humans and may include peripheral blood mononuclear cells (PBMCs).

The method described in the patent can be applied to T cells expressing either a Cß1 chain or a Cß2 chain. The TCR used in the method can have a desired antigen-specificity, allowing for customization based on specific therapeutic or research needs.

The patent also includes claims related to the use of biotinylated anti-Cß antibodies and anti-biotin MicroBeads for the isolation of T cells, as well as the use of the anti-Cß1 antibody JOVI.1.

In addition to the method, the patent also describes a kit comprising an anti-Cß antibody and a nucleotide acid encoding a TCR containing a Cß chain to which the antibody binds.

Overall, this patent presents a method for generating a T cell population enriched for T cells expressing a recombinant TCR, with potential applications in immunotherapy and research.

To know more about GlobalData’s detailed insights on MediGene, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies